Agenus | AGEN - Cost Of Sales


Agenus reported $642K in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Agenus USD 642K 399K Sep/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
CSL USD 3.87B 2.08B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Intrexon USD 1.01M 344K Jun/2024
J&J USD 7.97B 689M Dec/2025
Jiangsu Hengrui CNY 1.17B 86.74M Dec/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
MacroGenics USD 10.12M 34.18M Dec/2025
Merck EUR 2.29B 183M Dec/2025
Merck USD 3.32B 531M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Veracyte USD 39.28M 1.93M Dec/2025